Pertussis or 'whooping cough'
Conditions
Brief summary
Bp colonisation rate in Tdap-IPV and Td-IPV vaccination groups, with Bp colonisation defined as any positive Bp culture from nasal wash samples at any time point between Day 3 and Day 28 after challenge, Bp colonisation rate in Tdap-IPV vaccination groups, with Bp colonisation defined as any positive Bp culture from nasal wash samples at any time point between Day 3 and Day 28 after challenge
Interventions
DRUGAzitromycine 500 mg Teva
DRUGREVAXIS
Suspensie voor injectie in voorgevulde spuit.
Difterie
DRUGtetanus en poliomyelitis (geïnactiveerd) vaccin
DRUGgeadsorbeerd
DRUGbeperkte hoeveelheid antigen(en).
DRUGREPEVAX
DRUGin pre-filled syringe
Diphtheria
DRUGTetanus
DRUGcomponent) and Poliomyelitis (inactivated) Vaccine (adsorbed
DRUGreduced antigen(s) content)
Sponsors
Stichting Radboud University Medical Center
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Bp colonisation rate in Tdap-IPV and Td-IPV vaccination groups, with Bp colonisation defined as any positive Bp culture from nasal wash samples at any time point between Day 3 and Day 28 after challenge, Bp colonisation rate in Tdap-IPV vaccination groups, with Bp colonisation defined as any positive Bp culture from nasal wash samples at any time point between Day 3 and Day 28 after challenge | — |
Countries
Netherlands
Outcome results
None listed